Idiopathic Pulmonary Fibrosis Treatment Market to 2027 - Global Analysis and Forecasts by Drug Type (Pirfenidone, Nintedanib); Formulation (Tablets, Soft Capsules); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography
Report Code: TIPRE00005557 No. of Pages: 150 Category: Pharmaceuticals Status: Upcoming
MARKET INTRODUCTION
Idiopathic pulmonary fibrosis treatment is a type of interstitial lung disease in which the lung tissues become scarred and changes lung's ability to function normally. It is a progressive disease, over months to years, the normal lung tissue is replaced by more heavily scarred lung tissue, which makes it difficult to breathe and deliver needed oxygen to the body. Cause of disease may be smoking, genetics or working around dust or fumes for long period. The symptoms of disease are dry cough, shortness of breath, fatigue and weight loss.
MARKET DYNAMICS
The idiopathic pulmonary fibrosis treatment market is expected to grow exponentially in the forecast period owing to the factors such as growth in prevalence of fibrotic disease, increasing geriatric population and increase in cigarette smoking population. Furthermore, the introduction of effective drug treatment for idiopathic pulmonary fibrosis is anticipated to offer significant growth opportunities in the market during the forecast period.
MARKET SCOPE
The "Global Idiopathic Pulmonary Fibrosis Treatment Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a particular focus on the global market trend analysis. The report aims to provide an overview of the idiopathic pulmonary fibrosis treatment market with detailed market segmentation by drug type, formulation, distribution channel and geography. The global idiopathic pulmonary fibrosis treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading idiopathic pulmonary fibrosis treatment market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global idiopathic pulmonary fibrosis treatment market is segmented on the basis of drug type, formulation and distribution channel. Based on drug type, the market is classified as pirfenidone and nintedanib. Based on formulation the market is bifurcated into tablets and soft capsules. On the basis of distribution channel the idiopathic pulmonary fibrosis treatment market is classifies as hospital pharmacy, retail pharmacy and online pharmacy.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global idiopathic pulmonary fibrosis treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The idiopathic pulmonary fibrosis treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting idiopathic pulmonary fibrosis treatment market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Idiopathic pulmonary fibrosis treatment market in these regions.
MARKET PLAYERS
The reports cover key developments in the idiopathic pulmonary fibrosis treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from idiopathic pulmonary fibrosis treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for idiopathic pulmonary fibrosis treatment market in the global market. Below mentioned is the list of few companies engaged in the Idiopathic pulmonary fibrosis treatment market.
The report also includes the profiles of key idiopathic pulmonary fibrosis treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
Idiopathic pulmonary fibrosis treatment is a type of interstitial lung disease in which the lung tissues become scarred and changes lung's ability to function normally. It is a progressive disease, over months to years, the normal lung tissue is replaced by more heavily scarred lung tissue, which makes it difficult to breathe and deliver needed oxygen to the body. Cause of disease may be smoking, genetics or working around dust or fumes for long period. The symptoms of disease are dry cough, shortness of breath, fatigue and weight loss.
MARKET DYNAMICS
The idiopathic pulmonary fibrosis treatment market is expected to grow exponentially in the forecast period owing to the factors such as growth in prevalence of fibrotic disease, increasing geriatric population and increase in cigarette smoking population. Furthermore, the introduction of effective drug treatment for idiopathic pulmonary fibrosis is anticipated to offer significant growth opportunities in the market during the forecast period.
MARKET SCOPE
The "Global Idiopathic Pulmonary Fibrosis Treatment Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a particular focus on the global market trend analysis. The report aims to provide an overview of the idiopathic pulmonary fibrosis treatment market with detailed market segmentation by drug type, formulation, distribution channel and geography. The global idiopathic pulmonary fibrosis treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading idiopathic pulmonary fibrosis treatment market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global idiopathic pulmonary fibrosis treatment market is segmented on the basis of drug type, formulation and distribution channel. Based on drug type, the market is classified as pirfenidone and nintedanib. Based on formulation the market is bifurcated into tablets and soft capsules. On the basis of distribution channel the idiopathic pulmonary fibrosis treatment market is classifies as hospital pharmacy, retail pharmacy and online pharmacy.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global idiopathic pulmonary fibrosis treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The idiopathic pulmonary fibrosis treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting idiopathic pulmonary fibrosis treatment market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Idiopathic pulmonary fibrosis treatment market in these regions.
The reports cover key developments in the idiopathic pulmonary fibrosis treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from idiopathic pulmonary fibrosis treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for idiopathic pulmonary fibrosis treatment market in the global market. Below mentioned is the list of few companies engaged in the Idiopathic pulmonary fibrosis treatment market.
The report also includes the profiles of key idiopathic pulmonary fibrosis treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- AdAlta Limited
- ANGION BIOMEDICA CORP.
- Biogen
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Cipla Inc.
- F. Hoffmann-La Roche Ltd
- MediciNova, Inc.
- Promedior, Inc.
- Prometic Life Sciences Inc.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Idiopathic Pulmonary Fibrosis Treatment Market - By Drug Type
1.3.2 Idiopathic Pulmonary Fibrosis Treatment Market - By Formulation
1.3.3 Idiopathic Pulmonary Fibrosis Treatment Market - By Distribution Channel
1.3.4 Idiopathic Pulmonary Fibrosis Treatment Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. IDIOPATHIC PULMONARY FIBROSIS TREATMENT - GLOBAL MARKET OVERVIEW
6.2. IDIOPATHIC PULMONARY FIBROSIS TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DRUG TYPE
7.1. OVERVIEW
7.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
7.3. PIRFENIDONE
7.3.1. Overview
7.3.2. Pirfenidone Market Forecast and Analysis
7.4. NINTEDANIB
7.4.1. Overview
7.4.2. Nintedanib Market Forecast and Analysis
8. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - FORMULATION
8.1. OVERVIEW
8.2. FORMULATION MARKET FORECASTS AND ANALYSIS
8.3. TABLETS
8.3.1. Overview
8.3.2. Tablets Market Forecast and Analysis
8.4. SOFT CAPSULES
8.4.1. Overview
8.4.2. Soft Capsules Market Forecast and Analysis
9. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACY
9.3.1. Overview
9.3.2. Hospital Pharmacy Market Forecast and Analysis
9.4. RETAIL PHARMACY
9.4.1. Overview
9.4.2. Retail Pharmacy Market Forecast and Analysis
9.5. ONLINE PHARMACY
9.5.1. Overview
9.5.2. Online Pharmacy Market Forecast and Analysis
10. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Idiopathic Pulmonary Fibrosis Treatment Market Overview
10.1.2 North America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis
10.1.3 North America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Drug Type
10.1.4 North America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Formulation
10.1.5 North America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Idiopathic Pulmonary Fibrosis Treatment Market
10.1.6.1.1 United States Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.1.6.1.2 United States Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.1.6.1.3 United States Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.1.6.2 Canada Idiopathic Pulmonary Fibrosis Treatment Market
10.1.6.2.1 Canada Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.1.6.2.2 Canada Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.1.6.2.3 Canada Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.1.6.3 Mexico Idiopathic Pulmonary Fibrosis Treatment Market
10.1.6.3.1 Mexico Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.1.6.3.2 Mexico Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.1.6.3.3 Mexico Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Idiopathic Pulmonary Fibrosis Treatment Market Overview
10.2.2 Europe Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis
10.2.3 Europe Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Drug Type
10.2.4 Europe Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Formulation
10.2.5 Europe Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Idiopathic Pulmonary Fibrosis Treatment Market
10.2.6.1.1 Germany Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.2.6.1.2 Germany Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.2.6.1.3 Germany Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.2.6.2 France Idiopathic Pulmonary Fibrosis Treatment Market
10.2.6.2.1 France Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.2.6.2.2 France Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.2.6.2.3 France Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.2.6.3 Italy Idiopathic Pulmonary Fibrosis Treatment Market
10.2.6.3.1 Italy Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.2.6.3.2 Italy Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.2.6.3.3 Italy Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.2.6.4 Spain Idiopathic Pulmonary Fibrosis Treatment Market
10.2.6.4.1 Spain Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.2.6.4.2 Spain Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.2.6.4.3 Spain Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.2.6.5 United Kingdom Idiopathic Pulmonary Fibrosis Treatment Market
10.2.6.5.1 United Kingdom Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.2.6.5.2 United Kingdom Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.2.6.5.3 United Kingdom Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Overview
10.3.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Drug Type
10.3.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Formulation
10.3.5 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Idiopathic Pulmonary Fibrosis Treatment Market
10.3.6.1.1 Australia Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.3.6.1.2 Australia Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.3.6.1.3 Australia Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.3.6.2 China Idiopathic Pulmonary Fibrosis Treatment Market
10.3.6.2.1 China Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.3.6.2.2 China Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.3.6.2.3 China Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.3.6.3 India Idiopathic Pulmonary Fibrosis Treatment Market
10.3.6.3.1 India Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.3.6.3.2 India Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.3.6.3.3 India Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.3.6.4 Japan Idiopathic Pulmonary Fibrosis Treatment Market
10.3.6.4.1 Japan Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.3.6.4.2 Japan Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.3.6.4.3 Japan Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.3.6.5 South Korea Idiopathic Pulmonary Fibrosis Treatment Market
10.3.6.5.1 South Korea Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.3.6.5.2 South Korea Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.3.6.5.3 South Korea Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market Overview
10.4.2 Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Drug Type
10.4.4 Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Formulation
10.4.5 Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Idiopathic Pulmonary Fibrosis Treatment Market
10.4.6.1.1 South Africa Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.4.6.1.2 South Africa Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.4.6.1.3 South Africa Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.4.6.2 Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market
10.4.6.2.1 Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.4.6.2.2 Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.4.6.2.3 Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.4.6.3 U.A.E Idiopathic Pulmonary Fibrosis Treatment Market
10.4.6.3.1 U.A.E Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.4.6.3.2 U.A.E Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.4.6.3.3 U.A.E Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Idiopathic Pulmonary Fibrosis Treatment Market Overview
10.5.2 South and Central America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis
10.5.3 South and Central America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Drug Type
10.5.4 South and Central America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Formulation
10.5.5 South and Central America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Idiopathic Pulmonary Fibrosis Treatment Market
10.5.6.1.1 Brazil Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.5.6.1.2 Brazil Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.5.6.1.3 Brazil Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.5.6.2 Argentina Idiopathic Pulmonary Fibrosis Treatment Market
10.5.6.2.1 Argentina Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.5.6.2.2 Argentina Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.5.6.2.3 Argentina Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET, KEY COMPANY PROFILES
12.1. ADALTA LIMITED
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ANGION BIOMEDICA CORP.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. BIOGEN
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. BRISTOL-MYERS SQUIBB COMPANY
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. CIPLA INC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. F. HOFFMANN-LA ROCHE LTD
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. MEDICINOVA, INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. PROMEDIOR, INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. PROMETIC LIFE SCIENCES INC.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Idiopathic Pulmonary Fibrosis Treatment Market - By Drug Type
1.3.2 Idiopathic Pulmonary Fibrosis Treatment Market - By Formulation
1.3.3 Idiopathic Pulmonary Fibrosis Treatment Market - By Distribution Channel
1.3.4 Idiopathic Pulmonary Fibrosis Treatment Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. IDIOPATHIC PULMONARY FIBROSIS TREATMENT - GLOBAL MARKET OVERVIEW
6.2. IDIOPATHIC PULMONARY FIBROSIS TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DRUG TYPE
7.1. OVERVIEW
7.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
7.3. PIRFENIDONE
7.3.1. Overview
7.3.2. Pirfenidone Market Forecast and Analysis
7.4. NINTEDANIB
7.4.1. Overview
7.4.2. Nintedanib Market Forecast and Analysis
8. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - FORMULATION
8.1. OVERVIEW
8.2. FORMULATION MARKET FORECASTS AND ANALYSIS
8.3. TABLETS
8.3.1. Overview
8.3.2. Tablets Market Forecast and Analysis
8.4. SOFT CAPSULES
8.4.1. Overview
8.4.2. Soft Capsules Market Forecast and Analysis
9. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACY
9.3.1. Overview
9.3.2. Hospital Pharmacy Market Forecast and Analysis
9.4. RETAIL PHARMACY
9.4.1. Overview
9.4.2. Retail Pharmacy Market Forecast and Analysis
9.5. ONLINE PHARMACY
9.5.1. Overview
9.5.2. Online Pharmacy Market Forecast and Analysis
10. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Idiopathic Pulmonary Fibrosis Treatment Market Overview
10.1.2 North America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis
10.1.3 North America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Drug Type
10.1.4 North America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Formulation
10.1.5 North America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Idiopathic Pulmonary Fibrosis Treatment Market
10.1.6.1.1 United States Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.1.6.1.2 United States Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.1.6.1.3 United States Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.1.6.2 Canada Idiopathic Pulmonary Fibrosis Treatment Market
10.1.6.2.1 Canada Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.1.6.2.2 Canada Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.1.6.2.3 Canada Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.1.6.3 Mexico Idiopathic Pulmonary Fibrosis Treatment Market
10.1.6.3.1 Mexico Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.1.6.3.2 Mexico Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.1.6.3.3 Mexico Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Idiopathic Pulmonary Fibrosis Treatment Market Overview
10.2.2 Europe Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis
10.2.3 Europe Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Drug Type
10.2.4 Europe Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Formulation
10.2.5 Europe Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Idiopathic Pulmonary Fibrosis Treatment Market
10.2.6.1.1 Germany Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.2.6.1.2 Germany Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.2.6.1.3 Germany Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.2.6.2 France Idiopathic Pulmonary Fibrosis Treatment Market
10.2.6.2.1 France Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.2.6.2.2 France Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.2.6.2.3 France Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.2.6.3 Italy Idiopathic Pulmonary Fibrosis Treatment Market
10.2.6.3.1 Italy Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.2.6.3.2 Italy Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.2.6.3.3 Italy Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.2.6.4 Spain Idiopathic Pulmonary Fibrosis Treatment Market
10.2.6.4.1 Spain Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.2.6.4.2 Spain Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.2.6.4.3 Spain Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.2.6.5 United Kingdom Idiopathic Pulmonary Fibrosis Treatment Market
10.2.6.5.1 United Kingdom Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.2.6.5.2 United Kingdom Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.2.6.5.3 United Kingdom Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Overview
10.3.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Drug Type
10.3.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Formulation
10.3.5 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Idiopathic Pulmonary Fibrosis Treatment Market
10.3.6.1.1 Australia Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.3.6.1.2 Australia Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.3.6.1.3 Australia Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.3.6.2 China Idiopathic Pulmonary Fibrosis Treatment Market
10.3.6.2.1 China Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.3.6.2.2 China Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.3.6.2.3 China Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.3.6.3 India Idiopathic Pulmonary Fibrosis Treatment Market
10.3.6.3.1 India Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.3.6.3.2 India Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.3.6.3.3 India Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.3.6.4 Japan Idiopathic Pulmonary Fibrosis Treatment Market
10.3.6.4.1 Japan Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.3.6.4.2 Japan Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.3.6.4.3 Japan Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.3.6.5 South Korea Idiopathic Pulmonary Fibrosis Treatment Market
10.3.6.5.1 South Korea Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.3.6.5.2 South Korea Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.3.6.5.3 South Korea Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market Overview
10.4.2 Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Drug Type
10.4.4 Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Formulation
10.4.5 Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Idiopathic Pulmonary Fibrosis Treatment Market
10.4.6.1.1 South Africa Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.4.6.1.2 South Africa Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.4.6.1.3 South Africa Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.4.6.2 Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market
10.4.6.2.1 Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.4.6.2.2 Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.4.6.2.3 Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.4.6.3 U.A.E Idiopathic Pulmonary Fibrosis Treatment Market
10.4.6.3.1 U.A.E Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.4.6.3.2 U.A.E Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.4.6.3.3 U.A.E Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Idiopathic Pulmonary Fibrosis Treatment Market Overview
10.5.2 South and Central America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis
10.5.3 South and Central America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Drug Type
10.5.4 South and Central America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Formulation
10.5.5 South and Central America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Idiopathic Pulmonary Fibrosis Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Idiopathic Pulmonary Fibrosis Treatment Market
10.5.6.1.1 Brazil Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.5.6.1.2 Brazil Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.5.6.1.3 Brazil Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
10.5.6.2 Argentina Idiopathic Pulmonary Fibrosis Treatment Market
10.5.6.2.1 Argentina Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
10.5.6.2.2 Argentina Idiopathic Pulmonary Fibrosis Treatment Market by Formulation
10.5.6.2.3 Argentina Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET, KEY COMPANY PROFILES
12.1. ADALTA LIMITED
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ANGION BIOMEDICA CORP.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. BIOGEN
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. BRISTOL-MYERS SQUIBB COMPANY
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. CIPLA INC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. F. HOFFMANN-LA ROCHE LTD
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. MEDICINOVA, INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. PROMEDIOR, INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. PROMETIC LIFE SCIENCES INC.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies
1. AdAlta Limited
2. ANGION BIOMEDICA CORP.
3. Biogen
4. Boehringer Ingelheim International GmbH
5. Bristol-Myers Squibb Company
6. Cipla Inc.
7. F. Hoffmann-La Roche Ltd
8. MediciNova, Inc.
9. Promedior, Inc.
10. Prometic Life Sciences Inc.
1. AdAlta Limited
2. ANGION BIOMEDICA CORP.
3. Biogen
4. Boehringer Ingelheim International GmbH
5. Bristol-Myers Squibb Company
6. Cipla Inc.
7. F. Hoffmann-La Roche Ltd
8. MediciNova, Inc.
9. Promedior, Inc.
10. Prometic Life Sciences Inc.